Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00656552|
Recruitment Status : Unknown
Verified April 2008 by Cairo University.
Recruitment status was: Not yet recruiting
First Posted : April 11, 2008
Last Update Posted : April 11, 2008
Escitalopram has been claimed to have the highest selectivity for the human serotonin transporter relative to the noradrenaline or dopamine transporters. This might be associated with greater clinical efficacy. Most adverse events reported by escitalopram-treated patients are mild and transient.
In this study, we compare escitalopram with placebo in the treatment of PE.
|Condition or disease||Intervention/treatment||Phase|
|Premature Ejaculation||Drug: Escitalopram||Early Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study|
|Study Start Date :||May 2008|
|Estimated Primary Completion Date :||December 2008|
- Drug: Escitalopram
Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
- change in geometric mean IELT from baseline to four weeks. [ Time Frame: 4 week ]
- changes in the intercourse satisfaction domain values of IIEF(Arabic version). Assessment of possible side effects [ Time Frame: 4 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00656552
|Contact: Gamal S mohammed, M.B., B.Chfirstname.lastname@example.org|
|Kasr el ainy school of medicine , Cairo university||Not yet recruiting|
|Principal Investigator: Gamal S mohammed, M.B., B.Ch|
|Study Chair:||Hussein MH Ghanem, M D||Professor of Andrology & STDs|